Clinical Trials Logo

Filter by:
NCT ID: NCT05706649 Completed - Drowsiness Clinical Trials

A Study of Plant-based Diet on Postprandial Sleepiness

Start date: January 31, 2023
Phase: N/A
Study type: Interventional

This research aims to develop a better understanding and clinical knowledge of the effects of a plant-based diet on postprandial sleepiness.

NCT ID: NCT05706506 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Start date: March 8, 2023
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).

NCT ID: NCT05705544 Completed - Clinical trials for Peripheral Pulmonary Lesions

Robotic Versus Electromagnetic Bronchoscopy for Pulmonary LesIon AssessmeNT: (the RELIANT Trial)

RELIANT
Start date: March 6, 2023
Phase: N/A
Study type: Interventional

This is an investigator-initiated, cluster randomized controlled trial. The primary objective is to compare the diagnostic yield of the Ionā„¢ Endoluminal System (SSCB) to the ILLUMISITEā„¢ Platform (EMN bronchoscopy) in patients undergoing bronchoscopy for peripheral pulmonary lesion (PPL) evaluation.

NCT ID: NCT05705518 Completed - Dry Eye Clinical Trials

Artificial Tears, Tear Lipids and Tear Film Dynamics

AlconAT
Start date: January 30, 2023
Phase: Phase 4
Study type: Interventional

Dry eye disease (DED) is pervasive with some reports estimating over 16 million adults diagnosed in the United States. Currently, artificial tears remain an integral part of managing dry eyes and are mainly used for symptomatic relief. Recent studies have shown there may be therapeutic benefits with regular use of lipid-based artificial tears to improve the structure of the tear film, which may improve tear film stability and provide relief of symptoms. In this study the investigators propose to compare effects on the tear lipid film and its dynamics between 3 lipid based artificial tears and a widely available non-lipid based artificial tear.

NCT ID: NCT05705375 Completed - Waterpipe Size Clinical Trials

Effect of Waterpipe Size on Smoking Behavior and Exposures

Start date: April 22, 2022
Phase: N/A
Study type: Interventional

This project will generate novel evidence regarding the effect of waterpipe size on smoking behavior, toxicant exposures and subjective experiences among waterpipe smokers. Findings from this project will help the FDA in developing waterpipe size-specific regulations to curb waterpipe smoking in the US and protect public health.

NCT ID: NCT05704803 Completed - COVID-19 Pandemic Clinical Trials

COVID-19 Molecular OTC At Home Test

Start date: April 11, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the a molecular, OTC/At-Home COVID-19 Test in individuals presenting at a medical facility. In eligible subjects, nasal samples will be collected for use with the at-home molecular COVID-19 Test, which will be compared to the Zymo® rRT-PCR test results obtained via samples specified by the sponsor (e.g., AN [anterior nares] swab) to determine accuracy of the at-home/OTC molecular COVID-19 Test in detecting COVID-19 in participants.

NCT ID: NCT05704725 Completed - Clinical trials for Chorioretinal Vascular Disease

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Start date: January 23, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.

NCT ID: NCT05704556 Completed - Pain Clinical Trials

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Start date: February 27, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 and its metabolite in participants with severe or moderate renal impairment and healthy participants.

NCT ID: NCT05704543 Completed - Opioid Use Disorder Clinical Trials

Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations

Start date: March 1, 2023
Phase: Phase 4
Study type: Interventional

Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in 4 different quadrants of the abdomen for treatment of opioid use disorder (OUD). Injection locations are rotated to minimize irritation. Having 1 or more alternate injection sites is desirable for patients who may be taking SUBLOCADE for extended durations, based upon clinical response. The primary objective of this study is to assess the relative bioavailability of extended-release buprenorphine when administered at alternative injection locations (test treatments), in comparison to the abdomen (reference treatment).

NCT ID: NCT05704114 Completed - Acne Vulgaris Clinical Trials

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene 0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory hyperpigmentation in subjects with acne.